

Project generated by: **Contribution 1mission-1million
an Initiative of Boehringer Ingelheim
published in <https://www.heartofstroke.com/all-applications>**

Country: **Mexico**

Titel of the project: **Dimensions and Degree of Fibrosis of the left auricle by non-invasive means**

Project details

Pedro Iturralde Torres

Instituto Nacional de Cardiología, Ignacio Chavez

Award amount: €100,000

The degree of thromboembolism will be assessed as a risk factor for cerebral vascular disease by measuring the left auricle, the presence of thrombus through Tridimensional Echocardiography (3D) and fibrosis through nuclear magnetic resonance. Patients with rheumatic or degenerative mitral cardiomyopathy, systemic arterial hypertension or cardiac insufficiency

200 patients will be included with Paroxysmal Auricular Fibrillation, Persistent and Permanent with a high risk of cerebral embolismo using the CHADS-2 scale (Cardiac Failure, Hypertension, Age, Diabetes, Stroke-2), who shall go to the clinic for atrial fibrillation of the Department of Electrocardiography at the National Institute for Cardiology " Ignacio Chavez". With non-invasive measures, we will perform tridimensional measurements of the left auricle of the auricula with tridimensional echocardiography (3D), this being the first time that this equipment is used to this end on Mexican patients. It is used to look for data that might suggest the presence of blood clots in the cavity and with nuclear magnetic resonance we will assess the degree of fibrosis of the left auricle as a prognosis factor for the development of thromboembolism in patients with AF and in accordance with the international scale of light, moderate and severe. Patients at a high risk of embolism will be administered an oral prophylactic anti-coagulant. Patients with a high degree of fibrosis will be monitored at two years to assess their development of atrial fibrillation and stratify their risk of cerebral embolism, in which case we will also assess the suitability of the prophylactic use of the oral anti-coagulant

Audience

Type

- AF Patients
- General public

Location

Mexico, North America